Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.

Abstract excerpt

B cell prolymphocytic leukemia (B-PLL) is a rare and aggressive disease that is associated with poor survival. Although initially asymptomatic patients do not require therapy, most patients will progress and inevitably require treatment. More than 50% of patients with B-PLL carry abnormalities in the TP53 tumor suppressor gene and/or complex karyotype and show resistance to conventional chemotherapy. The efficacy...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenine
• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Aged